Hypothesis

Crocetin, acting at the blood‑brain barrier endothelium, enhances glymphatic waste clearance during non‑REM sleep by stabilizing HIF‑1α in vascular cells, which in turn amplifies norepinephrine‑driven perivascular oscillations and AQP4 polarization. This mechanism does not require crocetin to enter the brain parenchyma.

Rationale

• Crocetin binds VEGFR2 with high affinity and inhibits pro‑angiogenic signaling [3]. VEGFR2 activity influences endothelial calcium signaling and vascular tone, both of which modulate the low‑frequency oscillations that drive CSF influx [1].
• HIF‑1α is an oxygen‑sensitive transcription factor that regulates genes involved in vascular permeability and angiogenic balance. Stabilization of HIF‑1α in endothelial cells can increase NO production and modulate arterial pulsatility, key drivers of glymphatic flow.
• Oral crocetin achieves high plasma levels but shows no detectable brain parenchyma accumulation [2], suggesting its site of action is the neurovascular interface.
• Sleep‑dependent norepinephrine low‑amplitude oscillations are essential for glymphatic clearance; disrupting these oscillations impairs tracer influx [1]).

Predictions

1. In wild‑type mice, acute crocetin administration during the light phase will increase HIF‑1α protein levels specifically in cerebral microvascular endothelial cells (isolated via CD31+ sorting) without altering neuronal HIF‑1α.
2. This endothelial HIF‑1α upregulation will correlate with enhanced perivascular norepinephrine oscillation amplitude (measured by fiber‑optic NE sensors) and increased CSF‑ tracer influx (e.g., intrathecal Alexa‑647‑dextran) during NREM sleep.
3. Blocking VEGFR2 with a selective antagonist (e.g., SU5416) or using endothelial‑specific Vegfr2 knockout mice will abolish crocetin‑induced HIF‑1α stabilization and the accompanying boost in glymphatic clearance.
4. Conversely, genetic stabilization of endothelial HIF‑1α (via Hif‑1α‑ΔODD knock‑in) will mimic crocetin’s effect on glymphatic flow, rendering crocetin administration ineffective in these mice.

Experimental Approach

• Animal groups: WT, endothelial‑specific Vegfr2 KO, and Hif‑1α‑ΔODD knock‑in mice (n=8 per group).
• Treatments: Vehicle, crocetin (10 mg/kg i.p.), or crocetin + VEGFR2 antagonist administered 30 min before the onset of the light phase.
• Readouts:
  • Western blot/ELISA for HIF‑1α in CD31+ endothelial fractions vs. NeuN+ neuronal fractions.
  • In vivo two‑photon imaging of perivascular NE dynamics using GRAB_NE sensors.
  • Glymphatic clearance quantified by the ratio of brain‑to‑CSF fluorescence of intrathecal tracer after 30 min.
  • AQP4 polarization assessed by immunohistochemistry (perivascular vs. soma‑dominant staining).
• Controls: Sleep staging via EEG/EMG to ensure measurements are confined to NREM epochs.

Potential Outcomes and Falsifiability

If crocetin fails to raise endothelial HIF‑1α or improve glymphatic clearance in WT mice, or if VEGFR2 blockade does not attenuate these effects, the hypothesis would be falsified. Conversely, observing endothelial‑specific HIF‑1α enhancement, amplified NE oscillations, and increased tracer influx that are abolished by VEGFR2 loss or endothelial HIF‑1α neutralization would support the proposed mechanism. This framework directly tests whether a blood‑brain barrier‑restricted compound can modulate the brain’s nightly "autopsy" by tuning vascular signaling pathways.